Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
MD-76R is a radiographic contrast agent containing diatrizoate meglumine and diatrizoate sodium, administered by injection for diagnostic imaging procedures. It enhances visualization of internal organs and blood vessels during X-ray and fluoroscopic examinations. The drug works by absorbing X-rays due to its high iodine content, creating contrast between anatomical structures.
Approaching loss of exclusivity with moderate competitive pressure (30%), indicating a brand in transition that may consolidate to smaller support teams or shift focus to cost optimization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MD-76R offers stability in a mature, established product with steady demand in hospital and imaging center settings, but limited growth trajectory or innovation-focused career development. Career advancement depends on operational excellence, customer relationship management, and market access negotiation rather than drug development or clinical breakthroughs.
Worked on MD-76R at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.